Literature DB >> 2540534

Pain response post-chemonucleolysis or disc excision.

M D Brown1, J S Tompkins.   

Abstract

Eighty-five patients with proven lumbar disc displacement who had failed at least 3 months of conservative care were enrolled in this prospective study. The patients were self-selected into one of three treatment groups: collagenase, chymopapain, or surgery, based on information provided regarding the nature benefits and risks of each. Pain levels were self-recorded by patients in the post-treatment period, and follow-up physical examinations were performed and data were collected regarding hospital stay and return to activities for 3 months post-treatment. Patient's pain perception post-treatment was statistically lowest in the surgically treated group. The enzyme-injected patients reported higher levels of pain perception throughout the follow-up period, with collagenase-treated patients reporting more pain than chymopapain patients. Surgical patients had the most satisfactory outcome of treatment at 3 months. An explanation regarding the differences in pain response to the two enzymes is offered based on in vitro studies of the effects of the enzymes on the two major structural macromolecules of the connective tissue matrix.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540534     DOI: 10.1097/00007632-198903000-00013

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  2 in total

1.  Changes seen on magnetic resonance imaging in the intervertebral disc space after chemonucleolysis: a hypothesis concerning regeneration of the disc after chemonucleolysis.

Authors:  F Kato; K Mimatsu; N Kawakami; T Miura
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

2.  Chemonucleolysis versus surgical discectomy for sciatica secondary to lumbar disc herniation. A cost and quality-of-life evaluation.

Authors:  R Launois; B Henry; J R Marty; M Gersberg; C Lassale; M Benoist; J M Goehrs
Journal:  Pharmacoeconomics       Date:  1994-11       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.